| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Neoplasms | 174 | 2024 | 4312 | 9.670 |
Why?
|
| Nephrectomy | 101 | 2024 | 1016 | 9.540 |
Why?
|
| Carcinoma, Renal Cell | 135 | 2024 | 3217 | 8.340 |
Why?
|
| Prostatectomy | 116 | 2023 | 1956 | 7.890 |
Why?
|
| Prostatic Neoplasms | 170 | 2023 | 11336 | 4.940 |
Why?
|
| Prostate-Specific Antigen | 66 | 2023 | 2528 | 2.780 |
Why?
|
| Lymph Node Excision | 20 | 2017 | 1303 | 2.280 |
Why?
|
| Vena Cava, Inferior | 12 | 2023 | 458 | 2.140 |
Why?
|
| Carcinoma, Transitional Cell | 19 | 2010 | 800 | 1.690 |
Why?
|
| Neoplasm Recurrence, Local | 56 | 2021 | 9273 | 1.650 |
Why?
|
| Prostatic Hyperplasia | 20 | 2007 | 530 | 1.570 |
Why?
|
| Urinary Bladder Neoplasms | 26 | 2021 | 2276 | 1.540 |
Why?
|
| Prostate | 23 | 2021 | 1791 | 1.540 |
Why?
|
| Ureteral Neoplasms | 8 | 2008 | 110 | 1.420 |
Why?
|
| Thrombectomy | 9 | 2023 | 690 | 1.390 |
Why?
|
| Neoplasm Staging | 110 | 2017 | 11152 | 1.370 |
Why?
|
| Survival Rate | 85 | 2016 | 12721 | 1.360 |
Why?
|
| Neoplasms, Multiple Primary | 10 | 2008 | 586 | 1.230 |
Why?
|
| Cystectomy | 14 | 2021 | 697 | 1.130 |
Why?
|
| Laparoscopy | 16 | 2024 | 2147 | 1.060 |
Why?
|
| Watchful Waiting | 7 | 2023 | 509 | 0.960 |
Why?
|
| Neoplasm Invasiveness | 31 | 2020 | 3617 | 0.960 |
Why?
|
| Disease-Free Survival | 51 | 2020 | 6821 | 0.950 |
Why?
|
| Aged | 263 | 2023 | 168217 | 0.950 |
Why?
|
| Neoplastic Cells, Circulating | 7 | 2009 | 938 | 0.940 |
Why?
|
| Lymphatic Metastasis | 31 | 2017 | 2943 | 0.930 |
Why?
|
| Neoplasms, Second Primary | 8 | 2010 | 1056 | 0.920 |
Why?
|
| Male | 341 | 2023 | 358742 | 0.900 |
Why?
|
| Ureteroscopy | 7 | 2008 | 148 | 0.880 |
Why?
|
| Cryosurgery | 7 | 2012 | 475 | 0.880 |
Why?
|
| Androgen Antagonists | 13 | 2017 | 1442 | 0.870 |
Why?
|
| Microwaves | 12 | 2001 | 185 | 0.860 |
Why?
|
| Middle Aged | 262 | 2023 | 219560 | 0.840 |
Why?
|
| Venous Thrombosis | 6 | 2023 | 1292 | 0.840 |
Why?
|
| Kidney | 18 | 2018 | 7016 | 0.770 |
Why?
|
| Humans | 420 | 2024 | 758381 | 0.760 |
Why?
|
| Robotics | 7 | 2014 | 874 | 0.730 |
Why?
|
| Urinary Reservoirs, Continent | 4 | 2011 | 29 | 0.730 |
Why?
|
| Aged, 80 and over | 128 | 2020 | 58681 | 0.730 |
Why?
|
| Warm Ischemia | 5 | 2015 | 58 | 0.730 |
Why?
|
| Nomograms | 4 | 2017 | 237 | 0.690 |
Why?
|
| Prognosis | 80 | 2020 | 29558 | 0.690 |
Why?
|
| Renal Veins | 5 | 2017 | 102 | 0.680 |
Why?
|
| Nephrons | 9 | 2015 | 168 | 0.650 |
Why?
|
| Diathermy | 8 | 1998 | 17 | 0.650 |
Why?
|
| Follow-Up Studies | 84 | 2020 | 39060 | 0.640 |
Why?
|
| Urinary Diversion | 4 | 2011 | 135 | 0.640 |
Why?
|
| Postoperative Complications | 30 | 2021 | 15638 | 0.620 |
Why?
|
| Vascular Neoplasms | 3 | 2007 | 167 | 0.620 |
Why?
|
| Antineoplastic Agents, Hormonal | 9 | 2011 | 1530 | 0.610 |
Why?
|
| Survival Analysis | 41 | 2015 | 10112 | 0.600 |
Why?
|
| Treatment Outcome | 90 | 2024 | 64379 | 0.590 |
Why?
|
| Kidney Cortex | 2 | 2009 | 169 | 0.570 |
Why?
|
| Adenocarcinoma | 22 | 2008 | 6313 | 0.570 |
Why?
|
| Erectile Dysfunction | 5 | 2009 | 451 | 0.570 |
Why?
|
| Hyperthermia, Induced | 6 | 2002 | 416 | 0.530 |
Why?
|
| Disease Progression | 43 | 2023 | 13468 | 0.520 |
Why?
|
| Adenocarcinoma, Clear Cell | 8 | 2005 | 217 | 0.510 |
Why?
|
| Urodynamics | 8 | 2011 | 346 | 0.510 |
Why?
|
| Retrospective Studies | 93 | 2024 | 80170 | 0.510 |
Why?
|
| Angiomyolipoma | 4 | 2007 | 184 | 0.500 |
Why?
|
| Lymph Nodes | 11 | 2017 | 3485 | 0.490 |
Why?
|
| Tumor Burden | 9 | 2017 | 1893 | 0.490 |
Why?
|
| Neoadjuvant Therapy | 5 | 2017 | 2821 | 0.480 |
Why?
|
| Biopsy | 16 | 2023 | 6768 | 0.480 |
Why?
|
| Natural Orifice Endoscopic Surgery | 1 | 2015 | 119 | 0.450 |
Why?
|
| Adult | 150 | 2020 | 219916 | 0.440 |
Why?
|
| Kidney Pelvis | 6 | 2009 | 188 | 0.430 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 4 | 2017 | 81 | 0.430 |
Why?
|
| Seminal Vesicles | 7 | 2011 | 107 | 0.420 |
Why?
|
| Biopsy, Needle | 12 | 2014 | 1630 | 0.420 |
Why?
|
| Urology | 7 | 2017 | 423 | 0.410 |
Why?
|
| Urinary Incontinence | 5 | 2010 | 495 | 0.400 |
Why?
|
| Predictive Value of Tests | 33 | 2020 | 15225 | 0.390 |
Why?
|
| Antigens, CD | 13 | 2017 | 3997 | 0.380 |
Why?
|
| Minnesota | 10 | 2011 | 338 | 0.380 |
Why?
|
| Female | 144 | 2021 | 390316 | 0.380 |
Why?
|
| Glomerular Filtration Rate | 2 | 2017 | 2154 | 0.370 |
Why?
|
| Endoscopy | 4 | 2008 | 1834 | 0.370 |
Why?
|
| Circulatory Arrest, Deep Hypothermia Induced | 1 | 2011 | 82 | 0.370 |
Why?
|
| Salvage Therapy | 10 | 2021 | 1268 | 0.360 |
Why?
|
| Chemotherapy, Adjuvant | 13 | 2011 | 3527 | 0.360 |
Why?
|
| Radiotherapy, Adjuvant | 7 | 2014 | 1791 | 0.350 |
Why?
|
| Urine | 3 | 2010 | 363 | 0.350 |
Why?
|
| Renal Artery | 2 | 2009 | 351 | 0.350 |
Why?
|
| Adrenal Gland Neoplasms | 4 | 2005 | 733 | 0.350 |
Why?
|
| Angiolipoma | 1 | 2009 | 11 | 0.340 |
Why?
|
| BK Virus | 2 | 2020 | 123 | 0.340 |
Why?
|
| Embolization, Therapeutic | 2 | 2009 | 1407 | 0.330 |
Why?
|
| Thrombosis | 3 | 2023 | 2929 | 0.330 |
Why?
|
| Retroperitoneal Neoplasms | 3 | 2008 | 329 | 0.320 |
Why?
|
| Bone Neoplasms | 6 | 2011 | 2531 | 0.320 |
Why?
|
| Cystitis | 2 | 2008 | 96 | 0.320 |
Why?
|
| Peripheral Nerves | 2 | 2020 | 475 | 0.320 |
Why?
|
| Ploidies | 15 | 2007 | 275 | 0.320 |
Why?
|
| Angiotensin Receptor Antagonists | 1 | 2015 | 1016 | 0.320 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2015 | 1503 | 0.310 |
Why?
|
| Time Factors | 42 | 2020 | 39873 | 0.310 |
Why?
|
| Colonic Pouches | 1 | 2009 | 122 | 0.310 |
Why?
|
| Polyomavirus Infections | 2 | 2020 | 194 | 0.310 |
Why?
|
| Obesity, Morbid | 2 | 2016 | 1277 | 0.300 |
Why?
|
| Orchiectomy | 5 | 2011 | 470 | 0.300 |
Why?
|
| Health Status Indicators | 2 | 2014 | 970 | 0.300 |
Why?
|
| Algorithms | 11 | 2016 | 13959 | 0.300 |
Why?
|
| Extracorporeal Circulation | 1 | 2008 | 182 | 0.290 |
Why?
|
| Tumor Virus Infections | 2 | 2020 | 438 | 0.290 |
Why?
|
| Penis | 2 | 2008 | 213 | 0.290 |
Why?
|
| Brachytherapy | 3 | 2005 | 1236 | 0.280 |
Why?
|
| Preoperative Care | 7 | 2010 | 2249 | 0.280 |
Why?
|
| Necrosis | 7 | 2010 | 1604 | 0.280 |
Why?
|
| Kallikreins | 2 | 2020 | 230 | 0.280 |
Why?
|
| Cohort Studies | 33 | 2023 | 41252 | 0.280 |
Why?
|
| Disease Management | 2 | 2016 | 2500 | 0.280 |
Why?
|
| Osteoporotic Fractures | 1 | 2011 | 408 | 0.270 |
Why?
|
| Combined Modality Therapy | 18 | 2021 | 8530 | 0.270 |
Why?
|
| Risk Factors | 44 | 2023 | 73806 | 0.270 |
Why?
|
| Ligation | 1 | 2007 | 448 | 0.270 |
Why?
|
| Immunocompromised Host | 2 | 2009 | 856 | 0.260 |
Why?
|
| Proportional Hazards Models | 29 | 2016 | 12440 | 0.260 |
Why?
|
| Multivariate Analysis | 21 | 2016 | 12096 | 0.260 |
Why?
|
| Risk Assessment | 22 | 2020 | 23883 | 0.260 |
Why?
|
| Hypogonadism | 2 | 2009 | 800 | 0.250 |
Why?
|
| Cause of Death | 9 | 2010 | 3674 | 0.250 |
Why?
|
| Kidney Diseases | 6 | 2012 | 2083 | 0.250 |
Why?
|
| Urinary Fistula | 1 | 2005 | 43 | 0.250 |
Why?
|
| Receptors, Transforming Growth Factor beta | 1 | 2006 | 301 | 0.250 |
Why?
|
| Flutamide | 2 | 2006 | 95 | 0.250 |
Why?
|
| von Hippel-Lindau Disease | 2 | 2003 | 151 | 0.250 |
Why?
|
| Epigenesis, Genetic | 3 | 2017 | 3754 | 0.250 |
Why?
|
| Neoplasm Metastasis | 12 | 2011 | 4901 | 0.250 |
Why?
|
| DNA, Neoplasm | 11 | 2006 | 1745 | 0.240 |
Why?
|
| Urinary Bladder | 3 | 2007 | 1166 | 0.240 |
Why?
|
| Hematemesis | 1 | 2004 | 22 | 0.240 |
Why?
|
| Radiotherapy, High-Energy | 1 | 2005 | 228 | 0.240 |
Why?
|
| Carcinoma, Embryonal | 1 | 2004 | 37 | 0.240 |
Why?
|
| Tomography, X-Ray Computed | 11 | 2017 | 20500 | 0.240 |
Why?
|
| Urethra | 8 | 2015 | 406 | 0.240 |
Why?
|
| Vena Cava Filters | 1 | 2007 | 261 | 0.230 |
Why?
|
| Duodenal Neoplasms | 1 | 2004 | 115 | 0.230 |
Why?
|
| Receptors, Somatomedin | 1 | 2003 | 56 | 0.220 |
Why?
|
| Venae Cavae | 1 | 2003 | 41 | 0.220 |
Why?
|
| Epidemiologic Methods | 5 | 2011 | 1338 | 0.220 |
Why?
|
| Von Hippel-Lindau Tumor Suppressor Protein | 1 | 2005 | 305 | 0.220 |
Why?
|
| Perioperative Care | 1 | 2011 | 1028 | 0.210 |
Why?
|
| Age Factors | 13 | 2020 | 18357 | 0.210 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2017 | 2239 | 0.210 |
Why?
|
| Carcinoma | 5 | 2016 | 2330 | 0.210 |
Why?
|
| Catheter Ablation | 4 | 2010 | 2740 | 0.210 |
Why?
|
| Osteoporosis | 2 | 2011 | 1599 | 0.200 |
Why?
|
| Intraoperative Complications | 6 | 2015 | 1184 | 0.200 |
Why?
|
| Urologic Neoplasms | 3 | 2020 | 320 | 0.200 |
Why?
|
| Kaplan-Meier Estimate | 13 | 2020 | 6493 | 0.200 |
Why?
|
| Ischemia | 2 | 2007 | 1863 | 0.190 |
Why?
|
| Kidney Diseases, Cystic | 2 | 2005 | 183 | 0.190 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2004 | 412 | 0.190 |
Why?
|
| Cold Ischemia | 2 | 2015 | 67 | 0.190 |
Why?
|
| Organ Transplantation | 2 | 2009 | 1150 | 0.190 |
Why?
|
| Carcinoma, Papillary | 5 | 2015 | 785 | 0.180 |
Why?
|
| Receptors, Immunologic | 4 | 2009 | 1411 | 0.180 |
Why?
|
| Water | 3 | 2004 | 1402 | 0.180 |
Why?
|
| Patient Selection | 10 | 2012 | 4244 | 0.180 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2005 | 1110 | 0.180 |
Why?
|
| Membrane Glycoproteins | 3 | 2005 | 3705 | 0.180 |
Why?
|
| Molecular Targeted Therapy | 1 | 2012 | 2796 | 0.180 |
Why?
|
| Cholinergic Antagonists | 1 | 2001 | 164 | 0.170 |
Why?
|
| Hot Temperature | 3 | 2001 | 1434 | 0.170 |
Why?
|
| Adenoma, Oxyphilic | 3 | 2010 | 148 | 0.170 |
Why?
|
| Testicular Neoplasms | 2 | 2004 | 801 | 0.170 |
Why?
|
| Urinary Bladder, Neurogenic | 1 | 2001 | 174 | 0.170 |
Why?
|
| Heart Neoplasms | 1 | 2003 | 360 | 0.170 |
Why?
|
| Urinary Bladder Neck Obstruction | 2 | 2005 | 81 | 0.170 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2000 | 136 | 0.170 |
Why?
|
| Laser Coagulation | 1 | 2001 | 329 | 0.170 |
Why?
|
| Radiation Injuries | 2 | 2014 | 1182 | 0.160 |
Why?
|
| Transurethral Resection of Prostate | 4 | 2004 | 85 | 0.160 |
Why?
|
| DNA Methylation | 5 | 2015 | 4373 | 0.150 |
Why?
|
| Receptors, Androgen | 2 | 2004 | 1078 | 0.150 |
Why?
|
| Lipoma | 3 | 2008 | 292 | 0.150 |
Why?
|
| Gene Expression Regulation, Neoplastic | 6 | 2017 | 8506 | 0.150 |
Why?
|
| Adrenergic alpha-Antagonists | 4 | 2001 | 174 | 0.150 |
Why?
|
| Cystitis, Interstitial | 1 | 1998 | 66 | 0.150 |
Why?
|
| Testosterone | 1 | 2009 | 2471 | 0.150 |
Why?
|
| Cardiopulmonary Bypass | 2 | 2015 | 1093 | 0.150 |
Why?
|
| Androgens | 5 | 2011 | 1291 | 0.150 |
Why?
|
| Magnetic Resonance Imaging, Interventional | 1 | 2019 | 187 | 0.150 |
Why?
|
| Obesity | 3 | 2006 | 12870 | 0.150 |
Why?
|
| Ki-67 Antigen | 6 | 2009 | 631 | 0.150 |
Why?
|
| Hematuria | 2 | 2017 | 233 | 0.140 |
Why?
|
| Peptides | 3 | 2005 | 4341 | 0.140 |
Why?
|
| Urologic Surgical Procedures | 3 | 2006 | 309 | 0.140 |
Why?
|
| Microtubule-Associated Proteins | 4 | 2009 | 1074 | 0.140 |
Why?
|
| Heart Atria | 1 | 2003 | 1344 | 0.140 |
Why?
|
| Reproducibility of Results | 10 | 2019 | 20052 | 0.140 |
Why?
|
| Retroperitoneal Space | 1 | 2017 | 171 | 0.130 |
Why?
|
| Electrocoagulation | 4 | 2001 | 152 | 0.130 |
Why?
|
| Ultrasonography, Interventional | 2 | 2019 | 1489 | 0.130 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 3 | 2007 | 1086 | 0.130 |
Why?
|
| Ureter | 2 | 2010 | 375 | 0.130 |
Why?
|
| Leiomyosarcoma | 1 | 2000 | 424 | 0.130 |
Why?
|
| Immunohistochemistry | 16 | 2010 | 11070 | 0.130 |
Why?
|
| Metabolic Networks and Pathways | 2 | 2013 | 786 | 0.130 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2017 | 268 | 0.130 |
Why?
|
| beta-Galactosidase | 1 | 2017 | 574 | 0.130 |
Why?
|
| Ultrasonography, Doppler, Color | 1 | 2017 | 231 | 0.130 |
Why?
|
| Wisconsin | 1 | 2015 | 122 | 0.130 |
Why?
|
| Genomic Imprinting | 1 | 2017 | 330 | 0.130 |
Why?
|
| Length of Stay | 8 | 2016 | 6439 | 0.130 |
Why?
|
| Lung Neoplasms | 3 | 2011 | 13245 | 0.130 |
Why?
|
| Thrombolytic Therapy | 1 | 2004 | 2060 | 0.120 |
Why?
|
| Incidence | 9 | 2015 | 21273 | 0.120 |
Why?
|
| Tissue Array Analysis | 1 | 2017 | 551 | 0.120 |
Why?
|
| Intraoperative Care | 3 | 2010 | 766 | 0.120 |
Why?
|
| Lung Diseases | 2 | 2014 | 1910 | 0.120 |
Why?
|
| Urethral Neoplasms | 1 | 1994 | 37 | 0.120 |
Why?
|
| Quality of Life | 10 | 2014 | 13286 | 0.120 |
Why?
|
| Urothelium | 1 | 2016 | 277 | 0.120 |
Why?
|
| Caspase 3 | 1 | 2017 | 728 | 0.120 |
Why?
|
| Lymphangioleiomyomatosis | 1 | 1996 | 203 | 0.120 |
Why?
|
| Urinary Tract Infections | 2 | 2012 | 812 | 0.120 |
Why?
|
| RNA, Neoplasm | 2 | 2015 | 749 | 0.120 |
Why?
|
| Preoperative Period | 2 | 2015 | 553 | 0.110 |
Why?
|
| Iatrogenic Disease | 2 | 2009 | 538 | 0.110 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 2 | 2017 | 3774 | 0.110 |
Why?
|
| GRB10 Adaptor Protein | 1 | 2013 | 23 | 0.110 |
Why?
|
| Decision Trees | 1 | 2015 | 504 | 0.110 |
Why?
|
| Acetyl-CoA Carboxylase | 1 | 2013 | 72 | 0.110 |
Why?
|
| Mastectomy, Segmental | 1 | 2018 | 972 | 0.110 |
Why?
|
| Angiography | 2 | 2009 | 1599 | 0.110 |
Why?
|
| Pain, Postoperative | 3 | 2004 | 1721 | 0.110 |
Why?
|
| Ureteral Calculi | 3 | 2003 | 116 | 0.110 |
Why?
|
| Antigens, Neoplasm | 3 | 2015 | 1997 | 0.110 |
Why?
|
| Pentose Phosphate Pathway | 1 | 2013 | 126 | 0.110 |
Why?
|
| NF-E2-Related Factor 2 | 1 | 2015 | 374 | 0.110 |
Why?
|
| Pain | 2 | 2007 | 5065 | 0.110 |
Why?
|
| Abdominal Neoplasms | 3 | 2010 | 286 | 0.100 |
Why?
|
| Severity of Illness Index | 5 | 2008 | 15785 | 0.100 |
Why?
|
| Cadherins | 1 | 2017 | 898 | 0.100 |
Why?
|
| Chromatin | 2 | 2014 | 2938 | 0.100 |
Why?
|
| Matched-Pair Analysis | 2 | 2011 | 283 | 0.100 |
Why?
|
| Citric Acid Cycle | 1 | 2013 | 230 | 0.100 |
Why?
|
| Registries | 8 | 2011 | 8176 | 0.100 |
Why?
|
| Adrenalectomy | 2 | 2005 | 348 | 0.100 |
Why?
|
| Liver Neoplasms | 1 | 2008 | 4313 | 0.100 |
Why?
|
| Analysis of Variance | 4 | 2017 | 6233 | 0.100 |
Why?
|
| Gene Regulatory Networks | 1 | 2020 | 1740 | 0.100 |
Why?
|
| Smoking | 2 | 2008 | 9042 | 0.100 |
Why?
|
| Randomized Controlled Trials as Topic | 5 | 2017 | 10146 | 0.100 |
Why?
|
| Proto-Oncogene Proteins c-met | 1 | 2015 | 567 | 0.100 |
Why?
|
| Forecasting | 3 | 2006 | 2920 | 0.090 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2000 | 1152 | 0.090 |
Why?
|
| Reoperation | 4 | 2008 | 4282 | 0.090 |
Why?
|
| Adenoma, Chromophobe | 3 | 2005 | 16 | 0.090 |
Why?
|
| Nuclear Proteins | 3 | 2002 | 5787 | 0.090 |
Why?
|
| Diagnostic Errors | 2 | 1998 | 1263 | 0.090 |
Why?
|
| Diagnosis, Differential | 4 | 2007 | 12951 | 0.090 |
Why?
|
| Surgical Stapling | 1 | 2011 | 98 | 0.090 |
Why?
|
| Body Mass Index | 4 | 2016 | 12876 | 0.090 |
Why?
|
| Microsatellite Repeats | 2 | 2004 | 785 | 0.090 |
Why?
|
| Prospective Studies | 14 | 2018 | 54136 | 0.090 |
Why?
|
| Neoplasm Proteins | 4 | 2007 | 3609 | 0.090 |
Why?
|
| Comorbidity | 6 | 2014 | 10495 | 0.090 |
Why?
|
| Young Adult | 11 | 2017 | 58808 | 0.090 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2013 | 597 | 0.080 |
Why?
|
| Genome, Human | 3 | 2020 | 4415 | 0.080 |
Why?
|
| Fentanyl | 1 | 1992 | 433 | 0.080 |
Why?
|
| Cell Proliferation | 3 | 2017 | 10417 | 0.080 |
Why?
|
| Renal Insufficiency | 1 | 2015 | 809 | 0.080 |
Why?
|
| Carcinoma in Situ | 1 | 2014 | 796 | 0.080 |
Why?
|
| Histone-Lysine N-Methyltransferase | 1 | 2013 | 677 | 0.080 |
Why?
|
| Italy | 1 | 2011 | 839 | 0.080 |
Why?
|
| Antineoplastic Agents | 1 | 2012 | 13591 | 0.080 |
Why?
|
| Nitrofurantoin | 1 | 2008 | 19 | 0.080 |
Why?
|
| Chromatin Assembly and Disassembly | 1 | 2013 | 633 | 0.080 |
Why?
|
| Wilms Tumor | 2 | 1991 | 375 | 0.080 |
Why?
|
| Genetic Linkage | 2 | 2004 | 2381 | 0.080 |
Why?
|
| Anti-Infective Agents, Urinary | 1 | 2008 | 28 | 0.080 |
Why?
|
| Survival | 2 | 2006 | 160 | 0.080 |
Why?
|
| Equipment Design | 5 | 2007 | 3507 | 0.080 |
Why?
|
| Sarcoma | 3 | 2004 | 1785 | 0.080 |
Why?
|
| Cryotherapy | 1 | 2009 | 161 | 0.080 |
Why?
|
| Virus Integration | 2 | 2020 | 302 | 0.080 |
Why?
|
| Morphine | 1 | 1992 | 653 | 0.080 |
Why?
|
| Pressure | 1 | 2011 | 1155 | 0.080 |
Why?
|
| Sulfones | 2 | 2009 | 446 | 0.080 |
Why?
|
| Anastomosis, Surgical | 1 | 2011 | 983 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2020 | 3615 | 0.070 |
Why?
|
| Specimen Handling | 2 | 2010 | 707 | 0.070 |
Why?
|
| Kidney Function Tests | 2 | 2010 | 677 | 0.070 |
Why?
|
| Age Distribution | 2 | 2005 | 2882 | 0.070 |
Why?
|
| Regression Analysis | 3 | 2007 | 6353 | 0.070 |
Why?
|
| Kidney Transplantation | 3 | 2020 | 4217 | 0.070 |
Why?
|
| Purines | 2 | 2009 | 605 | 0.070 |
Why?
|
| Antibiotic Prophylaxis | 1 | 2012 | 642 | 0.070 |
Why?
|
| PTEN Phosphohydrolase | 1 | 2013 | 1113 | 0.070 |
Why?
|
| Cadaver | 1 | 2011 | 1345 | 0.070 |
Why?
|
| Linear Models | 4 | 2011 | 5861 | 0.070 |
Why?
|
| Hemangioma | 2 | 1993 | 727 | 0.070 |
Why?
|
| Anesthesia, Local | 2 | 2007 | 276 | 0.070 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 3 | 2004 | 11709 | 0.070 |
Why?
|
| Urachus | 1 | 2006 | 18 | 0.070 |
Why?
|
| Etoposide | 3 | 2004 | 630 | 0.070 |
Why?
|
| Catheterization | 2 | 2009 | 1426 | 0.070 |
Why?
|
| Double-Blind Method | 5 | 2007 | 12262 | 0.070 |
Why?
|
| DNA Mutational Analysis | 2 | 2013 | 4106 | 0.070 |
Why?
|
| Diet | 1 | 2004 | 8003 | 0.060 |
Why?
|
| Apoptosis | 3 | 2017 | 9468 | 0.060 |
Why?
|
| Lymphocyte Subsets | 1 | 2007 | 310 | 0.060 |
Why?
|
| Lod Score | 3 | 2004 | 602 | 0.060 |
Why?
|
| Mutation | 4 | 2015 | 29915 | 0.060 |
Why?
|
| Kidney Cortex Necrosis | 1 | 1985 | 6 | 0.060 |
Why?
|
| Anemia | 1 | 2015 | 1504 | 0.060 |
Why?
|
| Sensitivity and Specificity | 9 | 2007 | 14641 | 0.060 |
Why?
|
| History, 21st Century | 1 | 2011 | 1573 | 0.060 |
Why?
|
| Chromosomes, Human, Pair 8 | 1 | 2007 | 452 | 0.060 |
Why?
|
| History, 20th Century | 2 | 2011 | 2772 | 0.060 |
Why?
|
| Bleomycin | 2 | 2004 | 495 | 0.060 |
Why?
|
| Piperazines | 2 | 2009 | 2511 | 0.060 |
Why?
|
| Evaluation Studies as Topic | 1 | 2007 | 1628 | 0.060 |
Why?
|
| Blood Sedimentation | 1 | 2006 | 234 | 0.060 |
Why?
|
| Antigens, Nuclear | 2 | 2002 | 184 | 0.060 |
Why?
|
| Urinary Tract | 1 | 2008 | 309 | 0.060 |
Why?
|
| Adenocarcinoma, Mucinous | 1 | 1989 | 517 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2013 | 2443 | 0.060 |
Why?
|
| Prosthesis Design | 1 | 2011 | 2105 | 0.060 |
Why?
|
| Adipose Tissue | 2 | 2007 | 3299 | 0.060 |
Why?
|
| Tuberous Sclerosis | 4 | 1994 | 1030 | 0.060 |
Why?
|
| Lidocaine | 1 | 2007 | 537 | 0.060 |
Why?
|
| Quality Indicators, Health Care | 1 | 2014 | 1797 | 0.060 |
Why?
|
| Blood Coagulation | 1 | 2010 | 1149 | 0.060 |
Why?
|
| Creatinine | 2 | 2007 | 1892 | 0.060 |
Why?
|
| Histones | 1 | 2015 | 2577 | 0.060 |
Why?
|
| Escherichia coli Infections | 1 | 2008 | 523 | 0.060 |
Why?
|
| Patient-Centered Care | 1 | 2014 | 1415 | 0.060 |
Why?
|
| Chi-Square Distribution | 1 | 2010 | 3425 | 0.060 |
Why?
|
| Probability | 2 | 2008 | 2467 | 0.060 |
Why?
|
| Palladium | 1 | 2004 | 67 | 0.060 |
Why?
|
| Gene Expression Profiling | 2 | 2013 | 9405 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 1 | 2013 | 2858 | 0.060 |
Why?
|
| Repressor Proteins | 1 | 2014 | 2980 | 0.060 |
Why?
|
| Eosine Yellowish-(YS) | 1 | 2003 | 69 | 0.050 |
Why?
|
| Anesthesia, General | 2 | 2008 | 1165 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 5 | 2021 | 36285 | 0.050 |
Why?
|
| Imaging, Three-Dimensional | 1 | 2016 | 4048 | 0.050 |
Why?
|
| Arteries | 1 | 2008 | 1125 | 0.050 |
Why?
|
| Adrenal Glands | 1 | 2005 | 554 | 0.050 |
Why?
|
| Surgical Instruments | 1 | 2005 | 385 | 0.050 |
Why?
|
| Germ-Line Mutation | 4 | 2003 | 1840 | 0.050 |
Why?
|
| Hemoglobinometry | 1 | 2002 | 35 | 0.050 |
Why?
|
| Inhibitor of Apoptosis Proteins | 3 | 2009 | 197 | 0.050 |
Why?
|
| Medical Oncology | 1 | 2014 | 2312 | 0.050 |
Why?
|
| Radioisotopes | 1 | 2004 | 495 | 0.050 |
Why?
|
| Reagent Strips | 1 | 2002 | 39 | 0.050 |
Why?
|
| Vasodilator Agents | 2 | 2008 | 973 | 0.050 |
Why?
|
| Alprostadil | 1 | 2002 | 86 | 0.050 |
Why?
|
| Phenotype | 2 | 2017 | 16534 | 0.050 |
Why?
|
| Age of Onset | 4 | 2020 | 3298 | 0.050 |
Why?
|
| Laser Therapy | 2 | 2001 | 1089 | 0.050 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2006 | 726 | 0.050 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2004 | 380 | 0.050 |
Why?
|
| Chromogranins | 1 | 2002 | 161 | 0.050 |
Why?
|
| Metabolic Diseases | 1 | 2008 | 682 | 0.050 |
Why?
|
| Cisplatin | 3 | 2004 | 1645 | 0.050 |
Why?
|
| Pain Measurement | 2 | 2007 | 3527 | 0.050 |
Why?
|
| Apoptosis Regulatory Proteins | 1 | 2007 | 1134 | 0.050 |
Why?
|
| Pulmonary Embolism | 1 | 2015 | 2540 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 1 | 2 | 2002 | 635 | 0.050 |
Why?
|
| Health Status | 1 | 2014 | 4069 | 0.050 |
Why?
|
| Palpation | 5 | 2001 | 166 | 0.050 |
Why?
|
| Fluorocarbons | 1 | 2006 | 489 | 0.050 |
Why?
|
| Ultrasonography | 6 | 2012 | 5952 | 0.050 |
Why?
|
| Anesthesia, Spinal | 1 | 2004 | 280 | 0.050 |
Why?
|
| Cystoscopy | 2 | 2002 | 133 | 0.050 |
Why?
|
| Risk | 3 | 2008 | 9599 | 0.050 |
Why?
|
| MicroRNAs | 2 | 2015 | 3783 | 0.050 |
Why?
|
| Anesthetics, Local | 1 | 2007 | 1000 | 0.040 |
Why?
|
| CpG Islands | 2 | 2015 | 1221 | 0.040 |
Why?
|
| Markov Chains | 2 | 2000 | 965 | 0.040 |
Why?
|
| Sex Distribution | 1 | 2005 | 2283 | 0.040 |
Why?
|
| Blood Loss, Surgical | 2 | 2002 | 653 | 0.040 |
Why?
|
| Endoribonucleases | 1 | 2002 | 228 | 0.040 |
Why?
|
| Evidence-Based Medicine | 2 | 2011 | 3671 | 0.040 |
Why?
|
| 5-alpha Reductase Inhibitors | 1 | 2001 | 117 | 0.040 |
Why?
|
| Costs and Cost Analysis | 1 | 2006 | 1673 | 0.040 |
Why?
|
| Antigens, Viral, Tumor | 1 | 2020 | 153 | 0.040 |
Why?
|
| Estrogens | 1 | 2007 | 1520 | 0.040 |
Why?
|
| Iodine Radioisotopes | 1 | 2004 | 1032 | 0.040 |
Why?
|
| Chromosome Breakage | 1 | 2020 | 159 | 0.040 |
Why?
|
| Atrophy | 1 | 2005 | 1627 | 0.040 |
Why?
|
| Kinetics | 1 | 2008 | 6371 | 0.040 |
Why?
|
| Urination Disorders | 1 | 2001 | 240 | 0.040 |
Why?
|
| Cell Division | 3 | 2002 | 4459 | 0.040 |
Why?
|
| Nitric Oxide | 1 | 2009 | 2131 | 0.040 |
Why?
|
| Health Care Surveys | 2 | 2012 | 2432 | 0.040 |
Why?
|
| Phytotherapy | 1 | 2001 | 295 | 0.040 |
Why?
|
| Telomerase | 2 | 2002 | 745 | 0.040 |
Why?
|
| Confidence Intervals | 4 | 2010 | 2925 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 3 | 2002 | 5484 | 0.040 |
Why?
|
| Tuberculosis, Cardiovascular | 1 | 1999 | 8 | 0.040 |
Why?
|
| Acute Kidney Injury | 1 | 2012 | 1926 | 0.040 |
Why?
|
| Odds Ratio | 6 | 2010 | 9650 | 0.040 |
Why?
|
| Leukocytes, Mononuclear | 1 | 2006 | 1826 | 0.040 |
Why?
|
| Clinical Trials as Topic | 5 | 2005 | 7985 | 0.040 |
Why?
|
| Urinary Incontinence, Stress | 1 | 2001 | 181 | 0.040 |
Why?
|
| Cell Nucleus | 2 | 2003 | 2907 | 0.040 |
Why?
|
| Immunoenzyme Techniques | 1 | 2002 | 1705 | 0.040 |
Why?
|
| Complementary Therapies | 1 | 2003 | 486 | 0.040 |
Why?
|
| T-Lymphocyte Subsets | 1 | 2007 | 1807 | 0.040 |
Why?
|
| Transcription Factors | 2 | 2017 | 12096 | 0.040 |
Why?
|
| Staining and Labeling | 1 | 2003 | 1083 | 0.040 |
Why?
|
| Pedigree | 5 | 2010 | 4578 | 0.040 |
Why?
|
| Clinical Protocols | 1 | 2004 | 1436 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 2 | 2011 | 4353 | 0.040 |
Why?
|
| Cytoplasm | 1 | 2003 | 1514 | 0.040 |
Why?
|
| Job Satisfaction | 1 | 2002 | 539 | 0.040 |
Why?
|
| Multicenter Studies as Topic | 3 | 2004 | 1705 | 0.040 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2001 | 627 | 0.040 |
Why?
|
| Mycobacterium bovis | 1 | 1999 | 147 | 0.040 |
Why?
|
| Tumor Cells, Cultured | 2 | 2017 | 6127 | 0.040 |
Why?
|
| Aneurysm, Infected | 1 | 1999 | 81 | 0.040 |
Why?
|
| Blood Transfusion | 3 | 2016 | 1321 | 0.040 |
Why?
|
| Genetic Predisposition to Disease | 7 | 2010 | 17768 | 0.040 |
Why?
|
| Carboxypeptidases | 1 | 1998 | 154 | 0.040 |
Why?
|
| Dogs | 2 | 1994 | 3838 | 0.040 |
Why?
|
| Chromosome Mapping | 3 | 2004 | 4624 | 0.040 |
Why?
|
| Immunotherapy | 3 | 2005 | 4641 | 0.040 |
Why?
|
| Solubility | 2 | 2011 | 1087 | 0.040 |
Why?
|
| Genetic Variation | 4 | 2007 | 6548 | 0.040 |
Why?
|
| Transcriptional Activation | 1 | 2004 | 1753 | 0.040 |
Why?
|
| Cyclins | 1 | 2000 | 593 | 0.040 |
Why?
|
| Infusions, Intravenous | 2 | 2012 | 2210 | 0.040 |
Why?
|
| Serotonin | 1 | 2002 | 1040 | 0.040 |
Why?
|
| Calcium | 1 | 2010 | 5721 | 0.040 |
Why?
|
| Carcinosarcoma | 1 | 1998 | 104 | 0.040 |
Why?
|
| Postoperative Care | 3 | 2011 | 1471 | 0.040 |
Why?
|
| DNA-Binding Proteins | 1 | 2014 | 9575 | 0.040 |
Why?
|
| Genomics | 1 | 2013 | 5789 | 0.040 |
Why?
|
| Longitudinal Studies | 3 | 2004 | 14481 | 0.040 |
Why?
|
| Logistic Models | 4 | 2010 | 13276 | 0.040 |
Why?
|
| Hemorrhage | 1 | 2009 | 3400 | 0.040 |
Why?
|
| Hospital Mortality | 1 | 2011 | 5273 | 0.040 |
Why?
|
| Treatment Failure | 5 | 2003 | 2640 | 0.030 |
Why?
|
| Genome, Viral | 1 | 2020 | 658 | 0.030 |
Why?
|
| Flow Cytometry | 5 | 2008 | 5864 | 0.030 |
Why?
|
| Databases, Factual | 2 | 2020 | 7980 | 0.030 |
Why?
|
| Genital Neoplasms, Male | 1 | 1996 | 68 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2002 | 2504 | 0.030 |
Why?
|
| BCG Vaccine | 1 | 1999 | 371 | 0.030 |
Why?
|
| Ileum | 1 | 1998 | 555 | 0.030 |
Why?
|
| Adrenergic beta-Antagonists | 1 | 2001 | 1240 | 0.030 |
Why?
|
| Dysgerminoma | 1 | 1995 | 66 | 0.030 |
Why?
|
| Sex Factors | 2 | 2010 | 10505 | 0.030 |
Why?
|
| Protein Kinases | 1 | 2003 | 1610 | 0.030 |
Why?
|
| United States | 9 | 2014 | 72140 | 0.030 |
Why?
|
| Genes, Dominant | 1 | 1998 | 862 | 0.030 |
Why?
|
| Adolescent | 11 | 2008 | 87888 | 0.030 |
Why?
|
| Gene Expression | 2 | 2005 | 7583 | 0.030 |
Why?
|
| Thoracic Neoplasms | 2 | 2010 | 266 | 0.030 |
Why?
|
| X Chromosome | 1 | 1998 | 815 | 0.030 |
Why?
|
| Models, Statistical | 2 | 2007 | 5070 | 0.030 |
Why?
|
| Oxygen | 1 | 2006 | 4192 | 0.030 |
Why?
|
| Intestines | 1 | 2003 | 1906 | 0.030 |
Why?
|
| Postoperative Period | 3 | 2010 | 1812 | 0.030 |
Why?
|
| Genetic Testing | 2 | 2004 | 3530 | 0.030 |
Why?
|
| Academic Medical Centers | 2 | 2017 | 2751 | 0.030 |
Why?
|
| Anti-Bacterial Agents | 1 | 2012 | 7403 | 0.030 |
Why?
|
| Managed Care Programs | 1 | 1999 | 939 | 0.030 |
Why?
|
| Tumor Suppressor Protein p53 | 1 | 2004 | 2912 | 0.030 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2018 | 12076 | 0.030 |
Why?
|
| Antigens, Surface | 1 | 1998 | 1607 | 0.030 |
Why?
|
| Decision Support Techniques | 2 | 2000 | 1996 | 0.030 |
Why?
|
| Signal Transduction | 2 | 2015 | 23341 | 0.030 |
Why?
|
| Lymphangiomyoma | 1 | 1993 | 9 | 0.030 |
Why?
|
| Urography | 1 | 1994 | 312 | 0.030 |
Why?
|
| Ultrasound, High-Intensity Focused, Transrectal | 1 | 2012 | 6 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2010 | 7377 | 0.030 |
Why?
|
| Urinary Catheterization | 1 | 1993 | 198 | 0.030 |
Why?
|
| ROC Curve | 1 | 2000 | 3563 | 0.030 |
Why?
|
| Gonadotropin-Releasing Hormone | 2 | 2011 | 1153 | 0.030 |
Why?
|
| Drug Costs | 1 | 2000 | 1179 | 0.030 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 2 | 2011 | 3801 | 0.030 |
Why?
|
| Case-Control Studies | 6 | 2007 | 22031 | 0.020 |
Why?
|
| Self Administration | 1 | 1992 | 390 | 0.020 |
Why?
|
| Kidney Failure, Chronic | 2 | 2020 | 2457 | 0.020 |
Why?
|
| Second-Look Surgery | 1 | 2010 | 27 | 0.020 |
Why?
|
| Enzyme Inhibitors | 1 | 2001 | 3709 | 0.020 |
Why?
|
| Delphi Technique | 1 | 2014 | 829 | 0.020 |
Why?
|
| Vaginal Neoplasms | 1 | 1991 | 104 | 0.020 |
Why?
|
| Florida | 1 | 1992 | 431 | 0.020 |
Why?
|
| Urinary Bladder Diseases | 1 | 1991 | 169 | 0.020 |
Why?
|
| Health Care Costs | 2 | 2000 | 3245 | 0.020 |
Why?
|
| Vaginal Diseases | 1 | 1991 | 103 | 0.020 |
Why?
|
| Constriction | 1 | 2010 | 172 | 0.020 |
Why?
|
| Melanosis | 1 | 1991 | 93 | 0.020 |
Why?
|
| Pelvis | 2 | 2009 | 743 | 0.020 |
Why?
|
| Terminology as Topic | 1 | 1997 | 1533 | 0.020 |
Why?
|
| Testicular Diseases | 1 | 1990 | 73 | 0.020 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2000 | 2800 | 0.020 |
Why?
|
| Culture Media, Conditioned | 1 | 2011 | 522 | 0.020 |
Why?
|
| Light Coagulation | 1 | 1989 | 71 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2002 | 3586 | 0.020 |
Why?
|
| Image Processing, Computer-Assisted | 1 | 2006 | 8946 | 0.020 |
Why?
|
| Analgesia, Epidural | 1 | 1992 | 330 | 0.020 |
Why?
|
| Molecular Sequence Data | 3 | 2011 | 17617 | 0.020 |
Why?
|
| Animals | 5 | 2017 | 167777 | 0.020 |
Why?
|
| Polymorphism, Single Nucleotide | 2 | 2007 | 15773 | 0.020 |
Why?
|
| Actuarial Analysis | 1 | 1988 | 374 | 0.020 |
Why?
|
| Cell Cycle Proteins | 1 | 2000 | 3443 | 0.020 |
Why?
|
| Societies, Medical | 3 | 2010 | 3891 | 0.020 |
Why?
|
| Pelvic Neoplasms | 1 | 2010 | 248 | 0.020 |
Why?
|
| Fellowships and Scholarships | 1 | 2017 | 1116 | 0.020 |
Why?
|
| Nephrostomy, Percutaneous | 1 | 2009 | 82 | 0.020 |
Why?
|
| Remission Induction | 2 | 2007 | 2388 | 0.020 |
Why?
|
| Homeodomain Proteins | 1 | 2017 | 2413 | 0.020 |
Why?
|
| Cytogenetics | 1 | 2008 | 198 | 0.020 |
Why?
|
| Office Visits | 1 | 1992 | 596 | 0.020 |
Why?
|
| Attitude of Health Personnel | 2 | 2012 | 3867 | 0.020 |
Why?
|
| Sequence Analysis, RNA | 1 | 2015 | 2001 | 0.020 |
Why?
|
| Transplantation Immunology | 1 | 2009 | 532 | 0.020 |
Why?
|
| Lithotripsy | 1 | 1988 | 141 | 0.020 |
Why?
|
| Endoscopes | 1 | 1988 | 168 | 0.020 |
Why?
|
| Prevalence | 3 | 2006 | 15646 | 0.020 |
Why?
|
| Drug Evaluation | 1 | 2008 | 638 | 0.020 |
Why?
|
| Data Collection | 3 | 2002 | 3322 | 0.020 |
Why?
|
| Testis | 1 | 1990 | 794 | 0.020 |
Why?
|
| Observer Variation | 1 | 2012 | 2600 | 0.020 |
Why?
|
| Surgical Procedures, Operative | 1 | 1998 | 1911 | 0.020 |
Why?
|
| Recurrence | 2 | 2010 | 8426 | 0.020 |
Why?
|
| Interleukin-2 Receptor alpha Subunit | 1 | 2007 | 305 | 0.020 |
Why?
|
| Rectum | 2 | 2005 | 895 | 0.020 |
Why?
|
| Cross-Sectional Studies | 3 | 2012 | 25953 | 0.020 |
Why?
|
| Neoplasm, Residual | 1 | 2010 | 1007 | 0.020 |
Why?
|
| Constriction, Pathologic | 1 | 2009 | 1097 | 0.020 |
Why?
|
| Antibodies, Monoclonal | 1 | 2002 | 9160 | 0.020 |
Why?
|
| Genetic Markers | 2 | 2003 | 2608 | 0.020 |
Why?
|
| Heart Arrest | 1 | 2015 | 1494 | 0.020 |
Why?
|
| Consensus | 1 | 2014 | 3099 | 0.010 |
Why?
|
| Exudates and Transudates | 1 | 2005 | 174 | 0.010 |
Why?
|
| Administration, Oral | 1 | 2012 | 3993 | 0.010 |
Why?
|
| Mathematics | 1 | 2006 | 707 | 0.010 |
Why?
|
| Sarcoidosis | 1 | 1990 | 520 | 0.010 |
Why?
|
| Molecular Biology | 1 | 2008 | 580 | 0.010 |
Why?
|
| Europe | 1 | 2011 | 3420 | 0.010 |
Why?
|
| Cell Hypoxia | 1 | 2006 | 656 | 0.010 |
Why?
|
| Polymorphism, Genetic | 2 | 2007 | 4284 | 0.010 |
Why?
|
| Boston | 1 | 2016 | 9304 | 0.010 |
Why?
|
| Scavenger Receptors, Class A | 1 | 2003 | 52 | 0.010 |
Why?
|
| Alleles | 2 | 2007 | 6895 | 0.010 |
Why?
|
| Ureteroscopes | 1 | 2003 | 22 | 0.010 |
Why?
|
| Injections, Spinal | 1 | 2004 | 317 | 0.010 |
Why?
|
| Receptors, Scavenger | 1 | 2003 | 123 | 0.010 |
Why?
|
| Drainage | 1 | 2009 | 1161 | 0.010 |
Why?
|
| Chromogranin A | 1 | 2002 | 49 | 0.010 |
Why?
|
| Statistics, Nonparametric | 1 | 2008 | 2850 | 0.010 |
Why?
|
| England | 1 | 2004 | 524 | 0.010 |
Why?
|
| Blood Vessels | 1 | 2008 | 1112 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2008 | 15396 | 0.010 |
Why?
|
| Cytodiagnosis | 1 | 2006 | 442 | 0.010 |
Why?
|
| Models, Biological | 2 | 2010 | 9461 | 0.010 |
Why?
|
| Cell Count | 1 | 2006 | 1835 | 0.010 |
Why?
|
| Mice, Knockout | 1 | 2017 | 14354 | 0.010 |
Why?
|
| Patient Readmission | 1 | 2016 | 3261 | 0.010 |
Why?
|
| Random Allocation | 1 | 2006 | 2385 | 0.010 |
Why?
|
| Genes, Regulator | 1 | 2003 | 374 | 0.010 |
Why?
|
| Dilatation | 1 | 2003 | 307 | 0.010 |
Why?
|
| Cell Line, Transformed | 1 | 2003 | 869 | 0.010 |
Why?
|
| Recombinant Proteins | 1 | 2011 | 6520 | 0.010 |
Why?
|
| Neurosecretory Systems | 1 | 2002 | 221 | 0.010 |
Why?
|
| Microscopy, Confocal | 1 | 2007 | 1969 | 0.010 |
Why?
|
| Dyslipidemias | 1 | 2008 | 868 | 0.010 |
Why?
|
| Frameshift Mutation | 1 | 2003 | 388 | 0.010 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2008 | 1055 | 0.010 |
Why?
|
| Body Temperature | 1 | 2004 | 777 | 0.010 |
Why?
|
| Haplotypes | 1 | 2007 | 2764 | 0.010 |
Why?
|
| Cyclic GMP | 1 | 2002 | 395 | 0.010 |
Why?
|
| Cross-Cultural Comparison | 1 | 2004 | 635 | 0.010 |
Why?
|
| RNA, Messenger | 1 | 2015 | 12760 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 10747 | 0.010 |
Why?
|
| Genes, p53 | 1 | 2003 | 712 | 0.010 |
Why?
|
| Cold Temperature | 1 | 2004 | 780 | 0.010 |
Why?
|
| Codon, Nonsense | 1 | 2001 | 281 | 0.010 |
Why?
|
| Rabbits | 1 | 2006 | 4771 | 0.010 |
Why?
|
| Population Surveillance | 1 | 2010 | 2606 | 0.010 |
Why?
|
| Child | 5 | 2008 | 79813 | 0.010 |
Why?
|
| Private Practice | 1 | 2000 | 152 | 0.010 |
Why?
|
| Forkhead Transcription Factors | 1 | 2007 | 1611 | 0.010 |
Why?
|
| Patient Acceptance of Health Care | 1 | 1993 | 3175 | 0.010 |
Why?
|
| Suture Techniques | 1 | 2004 | 788 | 0.010 |
Why?
|
| Likelihood Functions | 1 | 2002 | 987 | 0.010 |
Why?
|
| Introns | 1 | 2002 | 978 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p27 | 1 | 2000 | 319 | 0.010 |
Why?
|
| Quality Improvement | 1 | 2014 | 3806 | 0.010 |
Why?
|
| Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2000 | 358 | 0.010 |
Why?
|
| Amino Acid Sequence | 1 | 2011 | 13447 | 0.010 |
Why?
|
| Administration, Intravesical | 1 | 1999 | 92 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2017 | 22006 | 0.010 |
Why?
|
| Graft Survival | 1 | 2009 | 3794 | 0.010 |
Why?
|
| Models, Genetic | 2 | 2000 | 3441 | 0.010 |
Why?
|
| Organ Specificity | 1 | 2003 | 1955 | 0.010 |
Why?
|
| Incidental Findings | 1 | 2004 | 694 | 0.010 |
Why?
|
| Genotype | 2 | 2007 | 12945 | 0.010 |
Why?
|
| Freezing | 1 | 1999 | 306 | 0.010 |
Why?
|
| Immunity | 1 | 2004 | 998 | 0.010 |
Why?
|
| Canada | 1 | 2004 | 2111 | 0.010 |
Why?
|
| Intraoperative Period | 1 | 1999 | 512 | 0.010 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2005 | 4567 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2011 | 4158 | 0.010 |
Why?
|
| Glutamate Carboxypeptidase II | 1 | 1998 | 80 | 0.010 |
Why?
|
| Urinary Retention | 1 | 1998 | 106 | 0.010 |
Why?
|
| Muscle, Smooth | 1 | 2002 | 924 | 0.010 |
Why?
|
| Proteinuria | 1 | 2000 | 594 | 0.010 |
Why?
|
| Cyclic AMP | 1 | 2002 | 1455 | 0.010 |
Why?
|
| Epithelium | 1 | 2002 | 1605 | 0.010 |
Why?
|
| Liver Transplantation | 1 | 2009 | 2325 | 0.010 |
Why?
|
| Models, Economic | 1 | 2002 | 715 | 0.010 |
Why?
|
| Lymphocytes | 1 | 2005 | 2610 | 0.010 |
Why?
|
| CD8-Positive T-Lymphocytes | 1 | 2011 | 4549 | 0.010 |
Why?
|
| Up-Regulation | 1 | 2006 | 4114 | 0.010 |
Why?
|
| Child, Preschool | 3 | 1991 | 42058 | 0.010 |
Why?
|
| Urination | 1 | 1998 | 202 | 0.010 |
Why?
|
| Chronic Disease | 1 | 2012 | 9266 | 0.010 |
Why?
|
| Fibrin Fibrinogen Degradation Products | 1 | 1999 | 418 | 0.010 |
Why?
|
| Radiography | 1 | 2007 | 6955 | 0.010 |
Why?
|
| Genetic Heterogeneity | 1 | 2000 | 723 | 0.010 |
Why?
|
| Graft Rejection | 1 | 2009 | 4426 | 0.010 |
Why?
|
| Data Interpretation, Statistical | 1 | 2006 | 2690 | 0.010 |
Why?
|
| Reference Values | 1 | 2003 | 4919 | 0.010 |
Why?
|
| Exons | 1 | 2002 | 2387 | 0.010 |
Why?
|
| Escherichia coli | 1 | 2008 | 4215 | 0.010 |
Why?
|
| Heart Transplantation | 1 | 2009 | 3220 | 0.010 |
Why?
|
| Chemoprevention | 1 | 1997 | 326 | 0.010 |
Why?
|
| Vinblastine | 1 | 1996 | 487 | 0.010 |
Why?
|
| Microcirculation | 1 | 1999 | 1273 | 0.010 |
Why?
|
| Insulin Resistance | 1 | 2008 | 3941 | 0.010 |
Why?
|
| Health Priorities | 1 | 1997 | 375 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2011 | 16886 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 1 | 2003 | 6068 | 0.010 |
Why?
|
| Urologic Diseases | 1 | 1997 | 248 | 0.010 |
Why?
|
| Feasibility Studies | 1 | 2004 | 5199 | 0.010 |
Why?
|
| Safety | 1 | 1998 | 1147 | 0.010 |
Why?
|
| Ambulatory Surgical Procedures | 1 | 1998 | 465 | 0.010 |
Why?
|
| Interferon-alpha | 1 | 1997 | 918 | 0.010 |
Why?
|
| Capillaries | 1 | 1996 | 744 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2006 | 8554 | 0.010 |
Why?
|
| Polycystic Kidney Diseases | 1 | 1994 | 133 | 0.010 |
Why?
|
| Cell Cycle | 1 | 2001 | 2930 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-bcl-2 | 1 | 1999 | 1404 | 0.010 |
Why?
|
| Hemoglobins | 1 | 1999 | 1519 | 0.010 |
Why?
|
| Melanoma | 1 | 1991 | 5691 | 0.010 |
Why?
|
| Family | 1 | 2003 | 3188 | 0.010 |
Why?
|
| Sequence Analysis, DNA | 1 | 2003 | 4711 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 1991 | 18125 | 0.010 |
Why?
|
| Drug Therapy, Combination | 1 | 2002 | 6293 | 0.010 |
Why?
|
| T-Lymphocytes | 1 | 2009 | 10171 | 0.010 |
Why?
|
| Heterozygote | 1 | 1998 | 2797 | 0.010 |
Why?
|
| Stents | 1 | 2003 | 3162 | 0.010 |
Why?
|
| Transplantation, Autologous | 1 | 1996 | 2114 | 0.010 |
Why?
|
| Base Sequence | 1 | 2002 | 12436 | 0.010 |
Why?
|
| Brain Neoplasms | 2 | 2003 | 8981 | 0.010 |
Why?
|
| Interleukin-2 | 1 | 1997 | 1888 | 0.010 |
Why?
|
| Vascular Diseases | 1 | 1999 | 1160 | 0.010 |
Why?
|
| Mice | 1 | 2017 | 81107 | 0.010 |
Why?
|
| Internet | 1 | 2002 | 3082 | 0.010 |
Why?
|
| Doxorubicin | 1 | 1996 | 2209 | 0.010 |
Why?
|
| Methotrexate | 1 | 1996 | 1719 | 0.010 |
Why?
|
| Phantoms, Imaging | 1 | 1998 | 2509 | 0.010 |
Why?
|
| Patient Satisfaction | 1 | 2002 | 3446 | 0.010 |
Why?
|
| Survivors | 1 | 1997 | 2371 | 0.000 |
Why?
|
| Infant | 1 | 1987 | 36054 | 0.000 |
Why?
|
| DNA | 1 | 1996 | 7199 | 0.000 |
Why?
|
| Research Design | 1 | 1997 | 6154 | 0.000 |
Why?
|